copper · Sebela Womens Hlth · NDA 218201
Miudella
Earliest generic entry, as listed
23 Jan 2037
Blocked by patent: US 10918516.
Listed patents · 14 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10918516 | drug product · sets the listed date | 23 Jan 2037 |
| US 11207209 | drug product | 16 Aug 2034 |
| US 10166141 | drug product | 13 Jun 2034 |
| US 9265652 | use U-4155 | 28 Apr 2034 |
| US 10022264 | drug product | 22 Mar 2034 |
| US 9180040 | drug product | 22 Mar 2034 |
| US 10398588 | drug product, use U-4155 | 24 Feb 2034 |
| US 9610191 | use U-4155 | 24 Feb 2034 |
| US 12138199 | drug product | 18 Oct 2033 |
| US 9089418 | drug product | 9 Apr 2033 |
| US 10159596 | drug product | 14 Aug 2032 |
| US 10188546 | drug product | 14 Aug 2032 |
| US 11850181 | drug product | 14 Aug 2032 |
| US 9427351 | drug product | 14 Aug 2032 |
Exclusivities · 1 unexpired
| NP | new product | 24 Feb 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 218201 · 001 · RLD | system, intrauterine | N/A | 23 Jan 2037 |